Close Menu

NEW YORK (360Dx) –The National Institute of Allergy and Infectious Diseases is sponsoring a clinical study to determine whether low levels of procalcitonin (PCT) can reliably reveal whether a person’s lower respiratory tract infection (LRTI) will improve with antibiotics.

Investigators at the NIAID-supported Antibacterial Resistance Leadership Group are collaborating in the PCT study with researchers and medical experts from BioMérieux, the diagnostics company based in Marcy-l'Étoile, France.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.